

**Overview of Development Pipeline Progress Status
in Third Quarter of Fiscal Year Ending March 31, 2018
- Conference Call -**

The followings summarize the changes in development pipeline status progress from the announcement of the previous second quarter financial results released on November 6, 2017. For the development pipeline progress status, please refer to pages 11 to 18 of the Third Quarter (Apr 1 - Dec 31, 2017) Flash Report.

<Development status in oncology area>

Japan

1 Opdivo Intravenous Infusion

The supplemental application for Opdivo was filed for the indication of malignant pleural mesothelioma in December 2017. Opdivo has been granted orphan drug designation and priority review. We expect to obtain approval within this year.

2 Yervoy Intravenous Infusion

The application of Yervoy in combination with Opdivo was submitted for first line renal cell carcinoma on January 15, 2018.

3 ONO-7701

Phase III study of an IDO1 inhibitor, ONO-7701, has started for malignant melanoma in combination with Opdivo.

4 ONO-4482/Relatlimab

Phase I/II study of an anti-LAG-3 antibody, ONO-4482, in combination with Opdivo has started for malignant melanoma.

South Korea and Taiwan

Opdivo Intravenous Infusion

Opdivo was approved for supplemental indication of gastric cancer or gastro-esophageal junction cancer after two or more prior chemotherapy regimens in Taiwan.

Europe and the US

Opdivo Intravenous Infusion

Phase II study of Opdivo in combination with Yervoy has started for prostate cancer in Europe and the US.

<Development status outside oncology area>

Japan

- 1 Onoact for Intravenous Infusion
Phase II / III study of Onoact has started for tachyarrhythmia upon sepsis.
- 2 ONO-4059/Tirabrutinib
Phase I study of a Btk inhibitor, ONO-4059, has started in healthy adults. This study is intended to carry out further clinical studies in Japan for Sjögren's syndrome, for which Gilead Sciences, an out-license partner, has been conducting clinical studies abroad.
- 3 ONO-8577
Phase II study of ONO-8577 having an effect of bladder smooth muscle relaxation was conducted for overactive bladder, but the development was discontinued because an anticipated efficacy could not be confirmed

Overseas

- 1 ONO-4474
Phase II study of a Trk inhibitor, ONO-4474, for the treatment of osteoarthritis was conducted, but the development was discontinued due to lack of anticipated efficacy, strategic reason, etc.